Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Armin Rashidi; Mehdi Hamadani; Mei-Jie Zhang; Hai-Lin Wang; Hisham Abdel-Azim; Mahmoud Aljurf; Amer Assal; Ashish Bajel; Asad Bashey; Minoo Battiwalla; Amer M Beitinjaneh; Nelli Bejanyan; Vijaya Raj Bhatt; Javier Bolaños-Meade; Michael Byrne; Jean-Yves Cahn; Mitchell Cairo; Stefan Ciurea; Edward Copelan; Corey Cutler; Andrew Daly; Miguel-Angel Diaz; Nosha Farhadfar; Robert P Gale; Siddhartha Ganguly; Michael R Grunwald; Theresa Hahn; Shahrukh Hashmi; Gerhard C Hildebrandt; H Kent Holland; Nasheed Hossain; Christopher G Kanakry; Mohamed A Kharfan-Dabaja; Nandita Khera; Yener Koc; Hillard M Lazarus; Jong-Wook Lee; Johan Maertens; Rodrigo Martino; Joseph McGuirk; Reinhold Munker; Hemant S Murthy; Ryotaro Nakamura; Sunita Nathan; Taiga Nishihori; Neil Palmisiano; Sagar Patel; Joseph Pidala; Rebecca Olin; Richard F Olsson; Betul Oran; Olov Ringden; David Rizzieri; Jacob Rowe; Mary Lynn Savoie; Kirk R Schultz; Sachiko Seo; Brian C Shaffer; Anurag Singh; Melhem Solh; Keith Stockerl-Goldstein; Leo F Verdonck; John Wagner; Edmund K Waller; Marcos De Lima; Brenda M Sandmaier; Mark Litzow; Dan Weisdorf; Rizwan Romee; Wael Saber

Journal article

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Armin Rashidi, Mehdi Hamadani, Mei-Jie Zhang, Hai-Lin Wang, Hisham Abdel-Azim, Mahmoud Aljurf, Amer Assal, Ashish Bajel, Asad Bashey, Minoo Battiwalla, Amer M Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Javier Bolaños-Meade, Michael Byrne, Jean-Yves Cahn, Mitchell Cairo, Stefan Ciurea, Edward Copelan, Corey Cutler Show all

Blood Adv | Published : 2019

DOI: 10.1182/bloodadvances.2019000050

Abstract

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-..

View full abstract